Axplora announces €50 Million Investment in GLP-1 Manufacturing at Mourenx (France) Site

Raubling  (Germany),  12  February  2025  –  Axplora,  a  global  leader  in  API  small  molecule  and  ADC manufacturing,  is  proud  to  announce  a  landmark  €50  million  investment  in  its  Mourenx  site  in Southwest  France,  securing  its  position  as  a  key player in the fight against cardiovascular and metabolic  diseases.  Specializing  in  large-scale  API  industrial chemistry and chromatography, this transformative project will enhance Mourenx’s capabilities, positioning it as a center of excellence in  the  Axplora  network  for  contract  manufacturing of APIs and drug substances for FDA-approved biologics.

This  investment  demonstrates  Axplora’s  dedication  to  partnering  with  leading  pharmaceutical companies,  fostering  innovation,  supporting  local  economic  growth,  and  delivering  life-changing therapies  to  patients  worldwide.  By  upgrading  Mourenx’s  infrastructure  and  capabilities,  Axplora will solidify its position in peptide purification in a biologics environment and support the development of next-generation therapies, including GLP-1 drugs that target diabetes and obesity—some of society’s most urgent health challenges.

“GLP-1 therapies represent a paradigm shift in medicine, offering targeted therapies for complex diseases with unprecedented efficacy and tolerability,” said Arul Ramadurai, Chief Commercial Officer. “This initiative, built on strong customer partnerships, reinforces Axplora’s role as a trusted partner in manufacturing life-changing, breakthrough medicines.”

“This project is testament to our pioneering expertise in industrial chromatography, and working closely with our client, we target having the facility BLA-ready in 15 months. To achieve this our internal teams are working closely with partners in a strong cross-functional project team, well-supported by the local authorities. We are looking forward to a bright future at Mourenx,” stated Dr.Pere Patón-Morales, Chief Operating Officer.

Construction  and  infrastructure  development  will  begin  immediately,  with  first  supplies  of  GLP-1 therapies expected in 2026. This investment ensures the Mourenx site will remain a key contributor to Axplora’s API network well into the 2030s and beyond.

About Axplora

Axplora is a trusted manufacturing partner to over 900 of the world’s leading pharmaceutical and biotech companies, formed from the integration of PharmaZell, Farmabios, and Novasep CDMO—three industry leaders with decades of experience in pharmaceutical manufacturing. Axplora delivers high-quality, reliable, and sustainable solutions across the pharmaceutical value chain.

With deep capabilities in complex chemistry and industrial manufacturing combined with an agile, explorer’s mindset, Axplora supports pharmaceutical and biotech companies in developing and producing life-changing therapies. PharmaZell and Farmabios are renowned for their expertise in active pharmaceutical ingredients (APIs), highly potent compounds, and regulatory excellence, while Novasep CDMO is a leader in small molecule and antibody-drug conjugates (ADCs) manufacturing while being a pioneer in purification technologies.

Axplora operates 9 API manufacturing sites across Europe and India, providing multi-site capacity to partners worldwide

Press contacts
Will Frost (UK/US)                              Thomas Goldberg (Europe)

+44 (0)7799652421                          +33 (0)6 03 78 55 63
press@axplora.com